NCT06780475

Brief Summary

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
11mo left

Started May 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress49%
May 2025May 2027

First Submitted

Initial submission to the registry

January 13, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 17, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

May 27, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

November 19, 2025

Status Verified

September 1, 2025

Enrollment Period

1.9 years

First QC Date

January 13, 2025

Last Update Submit

November 18, 2025

Conditions

Merkel Cell Carcinoma of Skin

Keywords

Merkel Cell Carcinoma of Skin

Outcome Measures

Primary Outcomes (1)

  • Anti-MCPyV functionality

    Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.

    Day 0 and Day 4

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients of Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or with an active follow-up beside dermatologist.

You may qualify if:

  • Patients \>= 18 years old;
  • Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
  • Informed for the study and no-opposed for participation;
  • Affiliated with a social security scheme or in an equivalent situation.

You may not qualify if:

  • Patients ongoing another interventional clinical trial;
  • Patients under guardianship or trusteeship;
  • Pregnancy or breastfeed;
  • Patients refusal.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dermato-oncology Department, Ambroise Paré Hospital, APHP

Boulogne-Billancourt, 92100, France

RECRUITING

Study Officials

  • Astrid Blom, MD

    Dermato-oncology Department, Ambroise Paré Hospital, APHP

    PRINCIPAL INVESTIGATOR

  • Yassine Taoufik, MD, PhD

    U1186 INSERM, PAUL BROUSSE Hospital, APHP

    STUDY DIRECTOR

Central Study Contacts

Astrid Blom, MD

CONTACT

+33 (01) 49 09 44 82astrid.blom@aphp.fr

Yassine Taoufik, MD, PhD

CONTACT

yassine.taoufik@aphp.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 13, 2025

First Posted

January 17, 2025

Study Start

May 27, 2025

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

November 19, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)